TY - JOUR
AU - Robert, Francisco
AB - Cancer Chemother Pharmacol (2016) 78:509–515 DOI 10.1007/s00280-016-3088-5 ORIGINAL ARTICLE Phase II study of a novel taxane (Cabazitaxel‑XRP 6258) in previously treated advanced non‑small cell lung cancer (NSCLC) patients 1 1 2 1 Ankit Madan · Benjamin S. Jones · Rodolfo Bordoni · Mansoor N. Saleh · 3 4 5 1 Mary S. Jerome · Deborah K. Miley · Bradford E. Jackson · Francisco Robert Received: 16 May 2016 / Accepted: 13 June 2016 / Published online: 14 July 2016 © Springer-Verlag Berlin Heidelberg 2016 Abstract to schedule B (SD = 38.46 %; 95 % CL 13.86, 68.42), Purpose Given the success of cabazitaxel in patients but this difference was not statistically significant ( P with prostate cancer who progressed after receiving prior value = 0.1156). There were two grade 5 toxicities from chemotherapy, its preclinical efficacy in various cell lines sepsis. Hematuria of any grade developed in greater per- and possible ability to cross blood-brain barrier, cabazi- centage of patients (35%) as compared to previous cabazi- taxel was hypothesized to increase objective response rate taxel phase 3 trial and led to change in our protocol. (ORR) in second-line setting in non-small cell lung cancer Conclusions Response to cabazitaxel in 
TI - Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients
JF - Cancer Chemotherapy and Pharmacology
DO - 10.1007/s00280-016-3088-5
DA - 2016-07-14
UR - https://www.deepdyve.com/lp/springer-journals/phase-ii-study-of-a-novel-taxane-cabazitaxel-xrp-6258-in-previously-FJRfDBHE4L
SP - 509
EP - 515
VL - 78
IS - 3
DP - DeepDyve
ER -